Merck announced positive top-line results from its pivotal Phase 3 trial evaluating the company’s 9-valent Human Papillomavirus vaccine, GARDASIL 9 in Japanese males ages 16 to 26 years. The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9 reduced the combined incidence of anogenital persistent infection caused by 9 types of HPV compared with a placebo. Merck plans to share these data with regulatory authorities in Japan and other countries around the world to support licensure for use in males. The full results also will be presented at an upcoming scientific congress. The clinical development program evaluating GARDASIL 9 in males also includes an ongoing confirmatory Phase 3 trial evaluating efficacy in preventing HPV oral persistent infection to support effectiveness against HPV-related oropharyngeal and other head and neck cancers
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Bicycle says 45% of patients respond to bladder cancer drug, EN reports
- Palantir, Dell Technologies named to join S&P 500: Morning Buzz
- Morning Movers: Boeing climbs after contract offer to Seattle workers union
- Evaxion Biotech reports 69% ORR in Phase 2 trial on EVX-01
- Summit Therapeutics price target raised to $19 from $13 at Citi